<SEC-DOCUMENT>0001193125-18-342870.txt : 20181206
<SEC-HEADER>0001193125-18-342870.hdr.sgml : 20181206
<ACCEPTANCE-DATETIME>20181206060908
ACCESSION NUMBER:		0001193125-18-342870
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181205
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181206
DATE AS OF CHANGE:		20181206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		181218670

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d679484d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): December&nbsp;5, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-36740</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">77-0357827</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>409 Illinois Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San
Francisco, CA 94158 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">978-1200</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report.) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Appointment of New Director </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;5, 2018, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the
&#147;Board&#148;) of FibroGen,&nbsp;Inc. (the &#147;Company&#148;), the Board appointed Maykin Ho, Ph.D., as a Class&nbsp;I director of the Company, effective December&nbsp;5, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Ho will hold office for the term expiring at the Company&#146;s 2021 annual meeting of stockholders and she will receive compensation
as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director of the Company under the Company&#146;s <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy, as amended, filed as Exhibit 10.6 with the Company&#146;s
Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the Securities and Exchange Commission (the &#147;SEC&#148;) on August&nbsp;7, 2018. Under the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director
Compensation Policy, Dr.&nbsp;Ho received 1) two option grants to purchase a total of 13,408 shares of the Company&#146;s common stock with an exercise price of $41.34 per share, and 2) a grant of restricted stock units covering 1,855 shares of the
Company&#146;s common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Ho and the Company have also entered into the Company&#146;s standard Indemnity Agreement,
effective December&nbsp;5, 2018, a form of which is filed as Exhibit 10.26 with the Company&#146;s registration statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> as amended, filed with the SEC on October&nbsp;23, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the Company&#146;s press release announcing Dr.&nbsp;Ho&#146;s appointment to the Board is attached as Exhibit&nbsp;99.1 to this
report. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d679484dex991.htm">Press Release titled &#147;FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors&#148; dated December 6, 2018 </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>F<SMALL>IBROGEN</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: December&nbsp;6, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Lowenstein</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Lowenstein</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Legal Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d679484dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g679484g1206041628391.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIBROGEN APPOINTS MAYKIN HO, PH.D., TO BOARD OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SAN FRANCISCO, December 6, 2018 &#151; FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutics, today announced the appointment of Maykin Ho, Ph.D., as an independent director to FibroGen&#146;s Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are delighted to welcome Dr.&nbsp;Maykin Ho, an accomplished leader with a great breadth of knowledge in the biotechnology industry, as a new Board
member,&#148; said Thomas B. Neff, CEO. &#147;Dr.&nbsp;Ho brings extensive experience in global strategy, finance, research, and marketing, and she will be an invaluable advisor as we continue to advance FibroGen&#146;s multiple late-stage product
programs, and move closer to the potential commercialization of roxadustat.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Ho has more than 30 years of experience in the healthcare and
finance industries. She serves on the boards of directors for Agios Pharmaceuticals, Parexel International Corporation, the Aaron Diamond AIDS Research Center, and the Institute for Protein Innovation.&nbsp;Dr.&nbsp;Ho is also a venture partner of
Qiming Venture Partners and a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong.&nbsp;She is a retired partner of the Goldman Sachs Group where she served as senior biotechnology analyst,
<FONT STYLE="white-space:nowrap">co-head</FONT> of healthcare for global investment research and advisory director for healthcare investment banking. Prior to Goldman Sachs, Dr.&nbsp;Ho held various managerial positions in licensing, strategic
planning, marketing and research at DuPont-Merck Pharmaceuticals and DuPont de Nemours&nbsp;&amp; Company.&nbsp;She was a postdoctoral fellow at Harvard Medical School and a graduate of the Advanced Management Program at The Fuqua School of
Business, Duke University. Dr.&nbsp;Ho received a Ph.D. in Microbiology and Immunology and a B.S. from the State University of New York, Downstate Medical Center. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I have known and worked with the FibroGen team over the years,&#148; said Dr.&nbsp;Ho. &#147;FibroGen continues to make progress on a diverse pipeline
and is poised to become a fully integrated company. I am honored to join the Board at such an exciting time in the company&#146;s growth and transformation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About FibroGen</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc., headquartered in San
Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#146;s Republic of China, is a leading biopharmaceutical company discovering and developing a pipeline of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutics.&nbsp;The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and
clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company&#146;s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity,
completing worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application (NDA) currently under review by the National Medical Products Administration (NMPA) in China. Our partner
Astellas submitted a NDA for the treatment of anemia in CKD patients on dialysis in Japan and currently under review by the Pharmaceuticals and Medical Devices Agency (PMDA). Roxadustat </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 1 of 2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS).&nbsp;Pamrevlumab, an anti-CTGF human
monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also
developing a biosynthetic cornea in China. For more information, please visit <U>www.fibrogen.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development of the
company&#146;s product candidates pamrevlumab and roxadustat, the potential safety and efficacy profile of our product candidates, and our clinical, regulatory plans, and those of our partners. These forward-looking statements include, but are not
limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as &#147;may,&#148; &#147;will&#148;, &#147;should,&#148; &#147;on track,&#148;
&#147;could,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;continue&#148; and similar words, although some forward-looking statements
are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various programs, including the
enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017, and our
Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarter ended September&nbsp;30, 2018 filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned
not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Karen L. Bergman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 (415) <FONT STYLE="white-space:nowrap">978-1433</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>kbergman@fibrogen.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 of 2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g679484g1206041628391.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g679484g1206041628391.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 2\# 2(  A$! Q$!_\0
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MB2ABC!MK%3CL1U%(H?1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)'N:*/YB#C)Z?UJWI22)I=OYP F9-\@ _B;D_J:P9Q;+I5O8V]HRK<7'E%E
M)9%8E\?@I'XUO37X1%6.-S._$:,,9/O[#O4M%PES2]"[4,MU;P,%FGBC8C(#
MN!G\Z?&'$2B1@SX&X@8!->*_&EB/$FG88C_0ST/^V:(1YG8TD[*Y[)_:-C_S
M^6__ ']7_&C^T;'_ )_+?_OZO^->"V?PP\2WUC;WD)M_*GC65,S'.&&1_.I_
M^%3>*O6V_P"_Y_PK3V<?YB>9]CWA)XI(O-25&C_O*P(_.ECECE0/&ZNAZ,IR
M#7FS>$-?M_A0VAPNHU 3-(RQR?ZQ-Y.W/N*O_"W0=8T+2+Q-6#1B:4-# S9*
M #D^V>/RJ'%6;N5=W.WCN[:63RXKB)W_ +JN":FKP7X6DGXD-EB?W5QU/N*]
MZHG'E=A1=T%%%%04%%%% !1110 4C.J*6=@J@9))P!4=Q/%:V\EQ.X2*)2[L
M3P .2:\!\3^,=7\;:P+#3A,MF[[+>VC.#)_M-_GBKA!R)E*Q[5+XM\/0R&.3
M6+,,#@CS0:O66IV.I1^997<-POK&X;%>0V/P7OYK97O-2A@E/)C1-V/QKG=9
M\-^(? %[#=QSLL9;$=U;DX)_ND?TJ_9Q>B8N9K='T7161X8O]0U+P_:7>J6G
MV6[D7+Q^OH<=L]<5KUB]"PHHHH **** "BBB@ HHHH **** &N6$;% "V#M!
MZ9JB-6@CE\B\/V:;&?GX4]>AZ=JT*BN+:"[A:*XB26,]589%-6)DGT,*6\N?
M.DGTN(BU?_6RR+\H/]]1U/O6%I^FQWOB&VM3(;B"T9Y][\^9&2#'@= N[(XZ
M[:VWLKQ7DM]+G+V:8\R*5N"?[BMV]ZQ-/U,6?BM;AHC;VDQ-D(WZ1!2,8/0C
M?N'MFK7D85)IVC+2[._J*YMH;NVDM[B-9(I%*LK#@@U)G-1W-S#:6TEQ.X2*
M-2S,3T K,Z':VIP.DQ2V=_/&MSY4NFEX4RI9)F)SC'9MFSIZUTEMJ!M;DRZS
M%]FN)/D23.8@.R@]C7-Z4USJ%WYZ0,K:@TDBM(2J12@\,/5MF!_P&NHL;)9+
MAAJ;?:+Z/GY_N;>S*O3%:2>NIA2A:-XZ7-E75U#*P93R"#D&O$_C7_R,FG?]
M>9_]#->OPZ6EI*&LY&A0MEHNJGZ#M7D'QJX\2:<?^G,_^AFG2^,TDWRZG>^'
M_%_AZV\-Z7!-J]LDL=I$CJ6Y4A "*TO^$V\,_P#09M?^^J\VTSX/?VCI5G??
MVML^TP)+M\KIN4''ZU;_ .%)?]1G_P A4W&G?<=Y=CK_ !QK+Q_#^ZU32;PJ
M6$;13Q'J"X'%9_PHU;4-8T"]FU&[DN9$NBBM(<D#:IQ47C#2O[#^#\FF>;YO
MV:.*/?C&[$BU7^"W_(LW_P#U^'_T!:5E[-AKS'F&@:^_AKQ#=ZE%&))@DT<0
M/3<S<$^U=*VG_$G68O[1+W@5AN5!)L./9:Q? ]M;7?Q&L8;L*8OM$C!6Z,P#
M%1^8%?1]:5)<KV)BKH\3\*?$?5]*UE-+\1,\D#2>4[S#$D+'@$^HKH/BYKFI
MZ,FD'3;V6V\TR[_+.-V N/YFN8^-%O!%XEM)8@JS2VA,N.^&(!/Z_E5KXK.\
MF@>$WDSYC0,6SZ[(\TDDW&7<+M)HSO[<\;^,8(8],%T8;6)(Y'B.W>X'+$]R
M?2ND37]4\ >"XSJ\TMUK5](QAMYGW"%1QD_S^IKL? %M%;>!='6) N^W61L=
MV;DG]:\K^+LDDOCJ*&8E84MHU4_[)8[C_GTI)J4N6V@WHKC;7_A87BV,W]O/
M=>02=K!_+0_[HJWI'C_Q%X5U@6'B1998 0)%E'SH/[RGN*]JM((;6SA@ME58
M8T"H%Z  <5Y=\;+:W^PZ3=;0+GSFBSW*;<_H0/SHC)2?*T#32O<VOBGJHB\
M%K:4%+^2.-64_>0_,?S KFO@MI4,MQJ6JR*&DAVP19_AR,L?Y4:E:3:E\!M-
MGP7>T(ESW"*[)^BG]*C^#.LPVU[?Z1,X5[G;-#G^(J,,/KC!_ T6M3:07]Y'
ML<LL<$+S2L$CC4L['H .2:P)O%?A6YC"3ZI92)D,%<Y&0<@UL:C:?;],N[/=
ML^T0O%NQTW*1G]:\*\8_#D>$M%CO_P"T/M&Z98=GEXZ@G/Z5$(QD]65)M;'N
M-IJ^GW]E)>6EW%+;19#R*>%P,G]*\=U;QSXC\7ZR^G>'!+%;DD(L7#NO]YCV
M%6?"\DD/P1\1/$2&\V49'H50'],UR_@RZ\3637DOANT\YF"K,PC#%1R0/;O^
M5:1@E=D.3=C>N?#GQ$T:W_M!;V>38-[+%/O8?AWKM/AQXYD\3P36-^%&H6ZA
MMRC E3IG'J#U^M<S_;OQ0_Z!LG_@.*K_  ^\/>(=/\>0WU[ID]O!(LWFN5PH
MW G'YXHDKQ=[ G9Z%2Y\?:SHGCO46ENIKFS@N9XUM6;Y>X4?@<5+=)\2]8A_
MM3_2HHC\Z11ML('LM9]A9Q7_ ,9GMYU#1G4Y7*D9!VEF _,"OH&E.2C:R'%-
MGDGP]^(=_<ZNFAZXYD:4E(9G&&#C^%OK7K=> ^,HUTWXN[[8!";JVFP/[QVY
MKWZHJ):-=1Q;V84445F6%%%% !4%TL[Q>7 P1F."_P#='<CWJ>B@#+OHX--T
MJXGCWIY41*A6ZGM^)/\ .L>YMK&+3K/3+JZ\Q?**2Q)AV9B.2!USG)K9U>#[
M8UI9''ER3!Y03U1/FQ^>VDGBM=.^SBVME\P/E(H@ S\$?CUZU2=D8N*E)G(V
M<FL6-M(Z7<L$$;".7[0-_EN!SA>N#E2/3-+/::E=ZA;Q:L9[K(69UMR"J(/]
MCU+8]> :Z&6'^S]6CU2\9"DX,4I'W83_  '\LJ3[BFZ5%/:PR:H(2T=V3(T.
M"7CC_@"_AR1ZL<57-U(E27PI_P##%66[M)M*CGCN6%U:/YXB)VG@DL,>ZEA^
M-;[6:2(DD$A616WI)G/7J/H:;%:6EYI\*S1Q7*A -S*#38])2V#_ &.XG@W=
M%+;U'T!_QJ6T:14EN:->(_&H$^(].PI/^AGH/]LU[=44MK;SL&F@BD8# +H#
MC\Z(2Y7<TDKJQG^&/^13T?\ Z\H?_0!6K2*JHH50%4#  ' I:EC./^* )^'V
MHX!/,?3_ *Z+6+\%P1X:O\@C_3#U'^PM>D21QRH4D170]589!IL4$4"E88DC
M4G)"*!_*KYO=Y2;:W/F+3=/U*]UJX.F+(+NV,ERFT'=\C=O?FNX@^,NJ6]IY
M%UI4;W:C:9"Q4$^XQ7L<=I;0OOBMXD<_Q*@!J";2--N)3+/I]K)(>K/"I)_'
M%6ZB>Z$H-;,\+TC1M:^(WBC[?J"N+4L#/,5PJH/X%_S[UTOQKC"PZ$D:':IF
M  '082O6HXTBC"1HJ(.BJ, 4R6W@GQYT,<FWIO4''YTO:>\GV#DTL8O@CCP/
MHF?^?./^5<Q\4O!MQKUM#JFG1^9=VJ%)(AUDCZ\>X.?SKT5$6- B*%51@*!@
M"EJ%)J5T4U=6/#=$^*VJZ'I\>G7]A]I: !$=V*. .S>M9ES+XA^)_B"(+ 4A
M3Y5P#Y<"D\DGN:]YN-*TZZD\RXL+:5_[SQ*3^9%3P6\-M'Y<$,<2#HJ*%'Z5
M?M$M4M2>5[-E2RT>TLM"AT=8P]K' ("K#[RXP<_6O#?%7@/5O"NHF\TY9I;%
M7WPSQ??B]FQZ>M?05! (P1UJ8S<6-Q3/![#XN^(+. 17,,%T5& [@JWXUDZU
MXI\0^.)(;-XC(@<,EO;QG!;ID_G7OTFAZ3*Y>33+1F)R285S_*K%M86=EQ:V
ML$&>OEQA?Y5?M(K5(7*^K.0\#>$[C3? ]QI.KHH:]>1I(P<E%=0N#[\5YI'_
M ,)#\+O$,Q6$R6[_ "[B#Y<Z \'/8U]!5'-!%<1F.:))$/574$'\#4JIJ[]1
MN/8\@G^-5R\!6VT=5F(X+29 /T[UVW@#7-9US17FUBR:&1&Q',5VB8'N![=*
MWDT32HG#QZ99JPZ$0+D?I5_I2E*+5D@2?5G@^AJW_"[F.TX_M"XYQ[/7O%0B
MTMEE\U;>(29SO"#.?K4U$Y<P15CP7X@JQ^+ (4D>9:\X_P!VO>JA>TMI)/,D
MMXGD_O,@)_.IJ)2NDNP)6"BBBH*"BBB@ HHHH 88T,HD*C> 5!]C_P#JH\I/
M-\W8/,*[=V.<>E/HH S-5B^WF+3@PV2,))QZQ@]/Q.!],UI8Q1@9S2T$J-FV
M11VT4,TDD8VF0Y< \$^N/6I:**"@HHHH **** "BBB@ HHHH **** "BBB@
BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
